SGP
SpyGlass Pharma, Inc.
25.60$
+2.7%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Cash Flow
All figures per share in USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|
| -0.20 | – | – | -0.26 | -0.28 | -0.68 | -0.44 | -1.39 | |
| 0.00 | – | – | 0.00 | 0.01 | 0.02 | 0.01 | 0.03 | |
| 0.01 | – | – | 0.03 | 0.03 | 0.08 | 0.06 | 0.17 | |
| 0.02 | – | – | 0.00 | 0.08 | -0.09 | 0.07 | 0.09 | |
| 0.01 | – | – | 0.00 | 0.01 | 0.03 | 0.06 | 0.10 | |
| – | – | – | -0.36 | 0.02 | -0.08 | -0.03 | -0.42 | |
| – | – | – | 0.00 | 0.00 | – | – | – | |
| 0.00 | – | – | -0.01 | -0.03 | 7.92 | 0.00 | 4.68 | |
| -0.06 | – | – | -0.64 | -0.29 | 7.15 | -0.47 | 2.87 | |
| -0.21 | – | – | -0.27 | -0.29 | -0.71 | -0.50 | -1.49 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.